Your Global Leader in Stem Cell Market Research
Miami, FL (May 11, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its Zofin™ therapy has been approved by Pakistani regulators to be used for a COVID-19 patient on compassionate grounds. [Read more…]
The immunotherapy field is booming, with cell therapies like chimeric antigen receptor (CAR) T cells taking the lead. According to one forecast, the market is expected to reach $6.1 billion in size by 2030 for CAR-T therapies alone. The FDA approved the world’s first CAR-T therapy, Kymriah, in 2017, and it is now available at over 130 treatment centers across the United States. [Read more…]
CLEVELAND, Ohio – Cell X Technologies’ CEO Peter Johnson MD, today announced an important new hire in Brian C. Handerhan, MBA, who will take on the newly created position of Vice President, Operations. In this role, he will oversee sales, marketing, product development, and product management to drive growth in all cell therapy markets served by Cell X. [Read more…]
Preservation of Cellular Therapies is a professional short course founded in 2003 to provide practical training for those individuals involved in the preservation of cellular therapies. This virtual course is associated with the Biopreservation Core Resource at the University of Minnesota and will be hosted on May 18-19, 2021.
With greater than 30 million cases and 946,000 deaths reported from COVID-19 worldwide, the novel Coronavirus represents one of the largest pandemics in modern history. Thankfully, it also represents the largest cooperative effort in human history.
Globally, scientists are exploring every potential weapon to suppress the threat, including vaccines, repurposed drugs, combination therapies, and as we explore here, cellular therapies with promising cell types such as natural killer (NK) cells and mesenchymal stem cells (MSCs).
In this interview with Dr. Robert Hariri, CEO of Celularity, Inc., we discuss the company’s cell therapeutics pipeline against COVID-19. Enjoy! [Read more…]
